On May 28, 2025 NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will debut its PanTracer Family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, May 30–June 3, 2025 (Press release, NeoGenomics Laboratories, MAY 28, 2025, View Source [SID1234653469]). The company will also unveil Paletrra, its new AI-driven spatial proteomics platform designed to provide clear, actionable insights from tissue samples.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The debut of the PanTracer Family and Paletrra represents a significant milestone for NeoGenomics and a step forward in precision oncology," said Warren Stone, President & Chief Operating Officer at NeoGenomics. "By equipping clinicians and drug developers with the tools to make faster, more informed decisions, we’re helping transform cancer care and accelerate innovation across the continuum of oncology diagnostics."
The PanTracer Family is designed to provide oncologists with timely and actionable genomic insights, supporting treatment decisions for patients with advanced-stage solid tumors. The portfolio includes PanTracer Tissue for comprehensive profiling from Formalin-Fixed, Paraffin-Embedded tissue, PanTracer LBx for liquid biopsy applications where tissue is unavailable or insufficient, and PanTracer Tissue + HRD, which adds homologous recombination deficiency testing to enhance therapy stratification. These assays can be used independently or as complementary tools, allowing clinicians to tailor their approach based on patient-specific needs. It also ensures fast, reliable access to the data needed to explore targeted therapies or clinical trials.
Paletrra is an AI-powered spatial proteomics platform that transforms precious tissue into high-plex, image-based insights. Built for translational research teams, Paletrra combines deep pathology expertise with integrated multimodal analysis to decode the tumor microenvironment and validate mechanisms of action. Paletrra provides a scalable, high-touch solution that enables both large biopharma and emerging biotech companies to make more informed therapeutic decisions—helping teams see the biology more clearly, faster, and with confidence.
NeoGenomics will showcase both solutions at Booth #11093 at the meeting, including an interactive experience, "Hey Neo," to help attendees explore how PanTracer supports therapy selection in real-world settings.
The company will also present a scientific poster at ASCO (Free ASCO Whitepaper) 2025, along with two abstracts published online. These achievements reinforce the company’s role as a research-driven partner to the biopharma community, supporting oncology drug development and clinical trials through cutting-edge diagnostics and scientific insight. The abstracts include:
Abstract #5568/Poster Board #466 (poster presentation): Real-world analysis of folate receptor alpha (FRα; FOLR1) expression in pan-tumor samples from over 6000 patients in the US
Abstract #e15180 (online publication): The cancer fusionome and overexpressed druggable oncogenic signals in K-RAS wild-type pancreatic cancer
Abstract #e15047 (online publication): Analytical validation and clinical performance of a plasma-based CGP assay, NEO | PanTracer LBx